Top 5 Stocks to Buy Now
→ SpaceX will mint billionaires. You won't be one of them. (From Behind the Markets) (Ad)tc pixel
NASDAQ:NXL

Nexalin Technology Q2 2024 Earnings Report

Nexalin Technology logo
$0.37 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$0.39 +0.02 (+5.71%)
As of 06/18/2026 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nexalin Technology EPS Results

Actual EPS
-$0.17
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nexalin Technology Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nexalin Technology Announcement Details

Quarter
Q2 2024
Date
8/8/2024
Time
N/A
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Nexalin Technology's Q2 2026 earnings is estimated for Wednesday, September 2, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Nexalin Technology's Q2 2024 Quarterly reportQuarterly report
(10-Q)

Nexalin Technology Earnings Headlines

Nexalin Overhauls Bylaws, Modernizes Corporate Governance Framework
June 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/nexalin-overhauls-bylaws-modernizes-corporate-governance-framework?utm_source=marketbeat.com&utm_medium=referral
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across ...
June 16, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/nexalin-technology-announces-two-clinical-abstracts-accepted-for-presentation-at-the-2026-nyc-neuromodulation-conference-highlighting-preliminary-clinical-results-across-anxiety-depression-1036253081
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
June 21 at 1:00 AM  |  Porter & Company (Ad)
Nexalin Technology, Inc. Announces Acceptance of Clinical Abstracts Showcasing DIFS™ Treatment Efficacy at 2026 NYC Neuromodulation Conference
June 16, 2026  |  quiverquant.comQ
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
June 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/16/3312711/0/en/nexalin-technology-announces-two-clinical-abstracts-accepted-for-presentation-at-the-2026-nyc-neuromodulation-conference-highlighting-preliminary-clinical-results-across-anxiety-de.html
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across ...
June 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/nexalin-technology-reports-compelling-clinical-131500924.html
See More Nexalin Technology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nexalin Technology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nexalin Technology and other key companies, straight to your email.

About Nexalin Technology

Nexalin Technology (NASDAQ:NXL) is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation.

The Nexalin device has received U.S. Food and Drug Administration 510(k) clearance for the treatment of generalized anxiety disorder and is marketed to healthcare providers, including psychiatrists, primary care physicians and behavioral health clinics. The therapy protocol typically involves a series of short, in-office treatment sessions during which patients remain awake and alert. Nexalin also supports ongoing clinical research to explore additional applications such as depression and stress-related conditions.

Headquartered in the United States, Nexalin Technology distributes its devices and training programs through a network of authorized dealers and directly to healthcare institutions. The company focuses on expanding adoption among mental health professionals by combining its regulatory-cleared device with physician training, clinical support services and patient education materials. As interest grows in nonpharmacological approaches to mental health, Nexalin aims to broaden its footprint across outpatient clinics and other care settings nationwide.

View Nexalin Technology Profile
Earnings Tools